Sunday 18 October 2026
Export BLSM’s income statement to Excel — free account
BlossomHill Therapeutics, Inc.
BLSM
Insiders bought in the last twelve months.
13.94
1.04
−6.94%
Follow BLSM
| Jun '26 | Mar '26 | Dec '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
5.42 | 7.40 | 8.97 | — |
+1 more quarter Free account |
Net Debt/EBITDA |
3.89 | 5.28 | 0.00 | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | — | |
Debt/Equity |
0.00 | 0.00 | 0.00 | — | |
Operating CF/Net income |
0.98 | 1.00 | — | 0.69 | |
Capex/Depreciation |
0.00 | (0.10) | — | (5.83) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | — | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | — | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | — | |
Share Based Compensation of Revenue |
0.00% | 0.00% | — | 0.00% | |
Free Cash Flow per Share |
(8.56) | (8.12) | — | (4.05) | |
Cash per Share |
35.14 | 44.96 | 0.00 | 0.00 | |
Shareholders Equity per Share |
30.23 | 40.58 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | — | 0.00 | |
Book value per Share |
30.23 | 40.58 | 0.00 | 0.00 | |
Free Cash Flow |
(23.23) | (20.95) | — | (9.74) | |
Working Capital |
82.35 | 103.55 | 123.35 | — | |
Capital Expenditures |
0.00 | (0.01) | — | (0.59) | |
Net Current Asset Value |
58.88 | 81.02 | 100.95 | — | |
| Other line items | |||||
Quick Ratio |
5.12 | 7.17 | 8.83 | — | |
Revenue per Share |
0.00 | 0.00 | — | 0.00 | |
Operating CF per Share |
(8.56) | (8.12) | — | (3.80) | |
Capex per Share |
0.00 | 0.00 | — | (0.25) | |
Capex to Sales |
0.00 | 0.00 | — | 0.00 |
Columns are period end dates · fundamentals updated 30 Sep 2026